派林生物：控股股东签署补充协议延长股份转让截止日至2026年6月30日

Core Viewpoint - The announcement by Palin Bio indicates a significant change in ownership structure, with China National Pharmaceutical Group set to become the actual controller of the company following the transfer of shares from the controlling shareholder, Shengbang Yinghao [1] Group 1: Share Transfer Agreement - Shengbang Yinghao has signed a supplementary agreement with China National Pharmaceutical Group regarding the transfer of 21.03% of its shares in Palin Bio [1] - The deadline for the completion of this share transfer has been extended to June 30, 2026, due to the ongoing state-owned enterprise and antitrust review processes [1] Group 2: Implications of Ownership Change - Following the completion of the share transfer, China National Pharmaceutical Group will become the actual controller of Palin Bio, indicating a shift in strategic direction and potential operational changes for the company [1]